Access the full text.
Sign up today, get DeepDyve free for 14 days.
Xiaoying Tang, Xiao Fu, Yang Liu, Di Yu, Sabrina Cai, Chunzhang Yang (2019)
Blockade of Glutathione Metabolism in IDH1-Mutated GliomaMolecular Cancer Therapeutics, 19
P. Ward, P. Ward, J. Cross, Chao Lu, Chao Lu, O. Weigert, Omar Abel-Wahab, R. Levine, D. Weinstock, K. Sharp, C. Thompson (2012)
Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate productionOncogene, 31
Lifeng Han, S. Eikenberry, Changhan He, Lauren Johnson, M. Preul, E. Kostelich, Y. Kuang (2019)
Patient-specific parameter estimates of glioblastoma multiforme growth dynamics from a model with explicit birth and death ratesMathematical biosciences and engineering : MBE, 16
KE Yen, M. Bittinger, SM Su, VR Fantin (2010)
Cancer-associated IDH mutations: biomarker and therapeutic opportunitiesOncogene, 29
Yehani Wedatilake, V. Plagnol, G. Anderson, S. Paine, Peter Clayton, Thomas Jacques, Shamima Rahman (2015)
Tubular aggregates caused by serine active site containing 1 (SERAC1) mutations in a patient with a mitochondrial encephalopathyNeuropathology and Applied Neurobiology, 41
S. Shi, R. Cote, Lin Wu, Cheng Liu, R. Datar, Yan Shi, Dongxin Liu, Hyoeun Lim, C. Taylor (2002)
DNA Extraction from Archival Formalin-fixed, Paraffin-embedded Tissue Sections Based on the Antigen Retrieval Principle: Heating Under the Influence of pHJournal of Histochemistry & Cytochemistry, 50
M. Waters, Angela Gupta, Karli Mockenhaupt, LaShardai Brown, Debolina Biswas, T. Kordula (2019)
RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiformeOncogenesis, 8
Hai Yan, D. Parsons, Geng-lin Jin, R. McLendon, B. Rasheed, Weishi Yuan, I. Kos, I. Batinic-Haberle, Siân Jones, G. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, Kenneth Kinzler, V. Velculescu, B. Vogelstein, D. Bigner (2009)
IDH1 and IDH2 mutations in gliomas.The New England journal of medicine, 360 8
Soojeong Chang, Sujin Yim, Hyunsung Park (2019)
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolismExperimental & Molecular Medicine, 51
P. Ward, Jay Patel, David Wise, O. Abdel-Wahab, Bryson Bennett, H. Coller, J. Cross, V. Fantin, C. Hedvat, A. Perl, J. Rabinowitz, M. Carroll, Shinsan Su, K. Sharp, R. Levine, C. Thompson (2010)
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer cell, 17 3
J. F. Dorsey, R. D. Salinas, M. Dang, M. Alonso‐Basanta, K. D. Judy, A. Maity, A. A. Pruitt (2020)
Abeloff's clinical oncology
Chun-Hau Chen, Swati Bhasin, Prateek Khanna, Mukta Joshi, P. Joslin, R. Saxena, Seema Amin, Suhu Liu, S. Sindhu, Sarah Walker, P. Catalano, D. Frank, S. Alper, M. Bhasin, R. Bhatt (2019)
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenograftsOncogenesis, 8
Luyan Mu, Wan-Hai Xu, Qingla Li, H. Ge, Hongbo Bao, S. Xia, J. Ji, Jie Jiang, Yuwen Song, Q. Gao (2017)
IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic TumoursJournal of Cancer, 8
Stefan Pusch, Felix Sahm, Jochen Meyer, Michel Mittelbronn, Christian Hartmann, A. Deimling (2011)
Scientific correspondenceNeuropathology and Applied Neurobiology, 37
W. Goh, B. Idris, R. Kandasamy, S. Shamsuddin, H. Jaafar, F. Ahmad (2019)
Pcr-rflp method enhance dna sequencing of idh1 somatic mutations detection in gliomasGULHANE MEDICAL JOURNAL
Bei Yang, C. Zhong, Yingjie Peng, Z. Lai, Jianping Ding (2010)
Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132HCell Research, 20
L. Dang, Shinsan Su (2017)
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Annual review of biochemistry, 86
H. Madala, S. Punganuru, Viswanath Arutla, S. Misra, T. Thomas, K. Srivenugopal (2018)
Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesCancers, 10
Gabriela Cruz, Indhira Oliveira, L. Moraes, Mário Paniago, M. Alves, A. Capellano, Nasjla Saba-Silva, S. Cavalheiro, J. Cerutti, S. Toledo (2014)
Analysis of KIAA1549–BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomasJournal of Neuro-Oncology, 117
C. Horbinski (2013)
What do we know about IDH1/2 mutations so far, and how do we use it?Acta Neuropathologica, 125
B. Stoddard, A. Dean, D. Koshland (1993)
Structure of isocitrate dehydrogenase with isocitrate, nicotinamide adenine dinucleotide phosphate, and calcium at 2.5-A resolution: a pseudo-Michaelis ternary complex.Biochemistry, 32 36
A. Pramono, G. Rather, Herry Herman, Keri Lestari, J. Bertino (2020)
NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An OverviewBiomolecules, 10
J. Dorsey, Ryan Salinas, Mai Dang, M. Alonso-Basanta, K. Judy, A. Maity, R. Lustig, John Lee, P. Phillips, A. Pruitt (2020)
Cancer of the Central Nervous System
S. Shi, R. Datar, Cheng Liu, Lin Wu, Zina Zhang, R. Cote, C. Taylor (2004)
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solutionHistochemistry and Cell Biology, 122
M. Böttcher, D. Mougiakakos (2019)
Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-HydroxyglutarateImmunometabolism
Felipe Núñez, Flor Mendez, Padma Kadiyala, Mahmoud Alghamri, S. Carney, M. Ljungman, Tingting Qin, M. Sartor, S. Venneti, C. Lyssiotis, J. Costello, C. Herting, D. Hambardzumyan, M. Figueroa, P. Lowenstein, M. Castro (2018)
GENE-35. IDH1-R132H INDUCES AN EPIGENETIC REPROGRAMMING IN GLIOMA IMPACTING MEDIAN SURVIVAL, DNA-DAMAGE RESPONSE AND RADIO-SENSITIVITYNeuro-Oncology
Julius July, D. Patricia, P. Gunawan, Handrianto Setiajaya, T. Ginting, T. Putra, Z. Wuisan, D. Budhiarko, N. Masykura, G. Prayogi, A. Utomo, S. Tandean, Michael Loe (2020)
Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatmentThe Pan African Medical Journal, 36
E. Pettersen, Thomas Goddard, Conrad Huang, Gregory Couch, Daniel Greenblatt, E. Meng, T. Ferrin (2004)
UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 25
Xiang Xu, Jingyue Zhao, Zhen Xu, B. Peng, Qiuhua Huang, E. Arnold, Jianping Ding (2004)
Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity*Journal of Biological Chemistry, 279
J. Kessler, T. Hohmann, A. Güttler, M. Petrenko, C. Ostheimer, Urszula Hohmann, M. Bache, F. Dehghani, D. Vordermark (2019)
Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the MechanismsCancers, 11
G. Stancheva, T. Goranova, M. Laleva, M. Kamenova, A. Mitkova, N. Velinov, G. Poptodorov, V. Mitev, R. Kaneva, N. Gabrovsky (2014)
IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma PatientsBioMed Research International, 2014
D. Parsons, Siân Jones, Xiaosong Zhang, Jimmy Lin, R. Leary, P. Angenendt, P. Mankoo, H. Carter, I. Siu, G. Gallia, A. Olivi, R. McLendon, B. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. Busam, H. Tekleab, L. Diaz, James Hartigan, Douglas Smith, R. Strausberg, S. Marie, S. Shinjo, Hai Yan, G. Riggins, D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. Velculescu, K. Kinzler (2008)
An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 321
D. Louis, H. Ohgaki, O. Wiestler, W. Cavenee, P. Burger, A. Jouvet, B. Scheithauer, P. Kleihues (2007)
The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 114
L. Huang (2019)
Friend or foe—IDH1 mutations in glioma 10 years onCarcinogenesis, 40
Yang Liu, Yanxin Lu, Aiguo Li, O. Celiku, Sue Han, Mingyu Qian, Chunzhang Yang (2020)
mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated GliomaCancers, 12
Luyuan Li, Xiaoyu Hu, J. Eid, A. Rosenberg, B. Wilky, Yuguang Ban, Xiaodian Sun, K. Galoian, J. DeSalvo, J. Yue, X. Chen, M. Blonska, J. Trent (2020)
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma GrowthCancers, 12
Dalissa Tejera, M. Kushnirsky, S. Gultekin, Min Lu, L. Steelman, M. Fuente (2020)
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I studyCNS Oncology, 9
Jiao Chen, Jie Yang, P. Cao (2016)
The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.Mini reviews in medicinal chemistry, 16 16
V. Rajendran (2016)
Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1.Molecular bioSystems, 12 7
L. Dang, Shengfang Jin, Shinsan Su (2010)
IDH mutations in glioma and acute myeloid leukemia.Trends in molecular medicine, 16 9
T. Sjöblom, Siân Jones, L. Wood, D. Parsons, Jimmy Lin, T. Barber, D. Mandelker, R. Leary, J. Ptak, N. Silliman, Steve Szabo, P. Buckhaults, Christopher Farrell, Paul Meeh, S. Markowitz, J. Willis, D. Dawson, J. Willson, A. Gazdar, James Hartigan, Leo Wu, Changsheng Liu, G. Parmigiani, B. Park, K. Bachman, N. Papadopoulos, B. Vogelstein, K. Kinzler, V. Velculescu (2006)
The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 314
S. Pusch, F. Sahm, J. Meyer, M. Mittelbronn, C. Hartmann, A. Deimling (2011)
Glioma IDH1 mutation patterns off the beaten track, 37
Diego Matteo, Adam Grunseth, E. Gonzalez, Stacy Anselmo, Madison Kennedy, Precious Moman, D. Scott, A. Hoang, C. Sohl (2017)
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiencyThe Journal of Biological Chemistry, 292
Various somatic isocitrate dehydrogenase 1 (IDH1) gene variants have been reported to drive lower‐grade gliomas and secondary glioblastomas. In the current study, we explored the IDH1 variants in the glioma biopsy samples of patients from Pakistan. We explored the incidence of isocitrate dehydrogenase 1 gene variants by hotspot sequencing in 80 formalin‐fixed paraffin‐embedded tissues of different types of glioma biopsy samples. Structural modeling of the identified variants in isocitrate dehydrogenase 1 protein was done to see their possible consequences. The frequently described p.Arg132 variants were not found in any of the glioma types. However, in our study, we identified nonsynonymous variants at the residues p.R109 and p.G136 in astrocytomas and p.R100 in oligodendroglioma. These variants are affecting a part of the conserved domain in isocitrate dehydrogenase 1. Both of p.R100 and p.R109 variants are rare and described before, whereas the p.G136 variant identified in this study has never been described previously. Structural modeling showed that variants of these residues would directly affect the substrate binding and hence the enzyme activity.
Annals of Human Genetics – Wiley
Published: Mar 1, 2021
Keywords: ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.